U.S. Capital Wealth Advisors’s Amicus Therapeutics FOLD Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,062	Closed	-$143K	–	1038
2025 Q4	$143K	Buy	+10,062	New	+$98.8K	﹤0.01%	952
2023 Q1	–	Sell	-1,200	Closed	-$14.7K	–	952
2022 Q4	$14.7K	Buy	+1,200	New	+$13.5K	﹤0.01%	1182

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

U.S. Capital Wealth Advisors's FOLD Position: Q1 2026 in Review

U.S. Capital Wealth Advisors sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 10,062 shares — an estimated $143K sold.

U.S. Capital Wealth Advisors first reported a position in FOLD in Q4 2022 and held it in 2 quarters. The position peaked at $143K in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

U.S. Capital Wealth Advisors reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
U.S. Capital Wealth Advisors sold 10,062 Amicus Therapeutics shares in Q1 2026, an estimated $143K.
U.S. Capital Wealth Advisors first reported a position in Amicus Therapeutics in Q4 2022 and held it in 2 quarters.
U.S. Capital Wealth Advisors's Amicus Therapeutics position peaked at $143K in Q4 2025.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.